ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company has ranked No. 4 on the Boston Globe’s 2022 Top Places to Work in the “Large Companies” category, marking its fourth consecutive year as an honoree.

The Boston Globe’s Top Places to Work, which will be featured in the print edition of Sunday’s paper, recognizes the most admired workplaces in the state, voted on by the people who know them best – their employees. The survey measures employee opinions about their company's leadership, appreciation, benefits and more. The winners are divided into four categories based on the number of employees: small (50-99); medium (100-249); large (250-999); and largest (1,000 or more). More than 94,000 employees at 381 companies completed surveys this year—a record high.

“At Beam, our vision is to provide life-long cures for patients suffering from serious diseases, and the ‘Beam Team’ is not only committed to making breakthroughs happen; they are committed to making Beam an exciting place to work, motivating colleagues and building a strong company culture in the process,” Susan O’Connor, chief human resource officer at Beam. “We are proud to be named, for the fourth year in a row, to this prestigious list of companies is Massachusetts who are committed to their missions, and importantly, each other.”

As an employer of choice, Beam is committed to fostering a culture that encourages employees to engage with colleagues. The company’s culture team frequently hosts programs on wellness, community engagement, diversity and inclusion, and team building to inspire, educate and care for employees. Events like Beam’s annual summer party, various walks and events in support of patient advocacy groups (including Light the Night and Walk with the Stars) and its “Balance @ Beam” wellness program supporting mental and financial health, demonstrate the company’s commitment to creating a culture that allows employees to thrive. Beam’s extensive benefits package includes programs like its "Take It as You Need It" paid time off policy, a five-week paid sabbatical after five years with an additional $5,000 stipend, medical benefits, a health and fitness reimbursement, 401k retirement plan, commuter reimbursement, family-forming benefits, an employee referral program and student loan refinancing.

In addition to its recognition as one of the Top Places to Work, Beam was named to the 2022 Best Places to Work list by the Boston Business Journal. For more information on careers at Beam, please visit https://beamtx.com/careers/.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Dan Budwick
1AB
dan@1abmedia.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.